SAGE Overview
Upcoming Projects (SAGE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SAGE)
-
A Second View: Checking in with a prescriber of ZURZUVAE (zuranolone) for the treatment of postpartum depression
Ticker: SAGE
Executed On: Jun 06, 2024 at 06:20 PM EDT -
Checking in with a prescriber of ZURZUVAE (zuranolone) for the treatment of postpartum depression
Ticker: SAGE
Executed On: Jun 04, 2024 at 05:40 PM EDT -
A Second Look: Discussing the potential of SAGE-718 for patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease.
Ticker: SAGE
Executed On: Jan 26, 2024 at 01:00 PM EST -
Discussing the potential of SAGE-718 for patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease.
Ticker: SAGE
Executed On: Jan 25, 2024 at 12:00 PM EST -
Discussing how access and pricing are being considered for Zurzuvae (zuranolone).
Ticker: SAGE
Executed On: Jan 16, 2024 at 01:30 PM EST -
A Third Look: Discussing the recent approval of ZURZUVAE (zuranolone) in treating women for postpartum depression (PPD) with a psychiatrist
Ticker: SAGE
Executed On: Aug 30, 2023 at 02:00 PM EDT -
A Second Look: Discussing the recent approval of ZURZUVAE (zuranolone) in treating women for postpartum depression (PPD) with a psychiatrist
Ticker: SAGE
Executed On: Aug 17, 2023 at 04:00 PM EDT -
Discussing the recent approval of ZURZUVAE (zuranolone) in treating women for postpartum depression (PPD) with a psychiatrist
Ticker: SAGE
Executed On: Aug 16, 2023 at 04:00 PM EDT -
A Third Look: Discussing the potential of Zuranolone(SAGE-217/BIIB125) in patients with major depressive disorder(MDD) and postpartum depression(PPD).
Ticker: SAGE
Executed On: Jun 22, 2023 at 02:00 PM EDT -
A Second Look: Discussing the potential of Zuranolone(SAGE-217/BIIB125) in patients with major depressive disorder(MDD) and postpartum depression(PPD).
Ticker: SAGE
Executed On: Jun 21, 2023 at 10:00 AM EDT -
Discussing the potential of Zuranolone(SAGE-217/BIIB125) in patients with major depressive disorder(MDD) and postpartum depression(PPD).
Ticker: SAGE
Executed On: Jun 20, 2023 at 10:00 AM EDT -
A second look at Relmada Therapeutics' novel NMDAR channel blocker, REL-1017, as monotherapy for the treatment of MDD and its P2 data
Tickers: RLMD, JNJ, AXSM, SAGE
Executed On: Aug 30, 2022 at 06:30 PM EDT -
A look at the MDD treatment landscape and the potential of Zuranolone
Ticker: SAGE
Executed On: Jul 27, 2022 at 04:00 PM EDT -
Discussing the essential tremor treatment landscape, specifically PRAX-944 and SAGE-324
Tickers: PRAX, SAGE
Executed On: Jul 19, 2022 at 05:15 PM EDT -
A Second Look at the Skylark study and discussing Zuranolone in postpartum depression (PPD)
Tickers: SAGE, BIIB
Executed On: Jun 21, 2022 at 06:00 PM EDT -
A Third Look at the Skylark study and discussing Zuranolone in postpartum depression (PPD)
Tickers: SAGE, BIIB
Executed On: Jun 21, 2022 at 04:45 PM EDT -
A Look at the Skylark study and discussing Zuranolone in postpartum depression (PPD)
Tickers: SAGE, BIIB
Executed On: Jun 13, 2022 at 01:00 PM EDT -
A look at the potential of Zuranolone after the CORAL data release
Ticker: SAGE
Executed On: Mar 10, 2022 at 03:00 PM EST -
As data continues to released on Zuranolone in major depressive disorder, what does the CORAL study say about the drug's future?
Tickers: SAGE, BIIB
Executed On: Mar 04, 2022 at 03:00 PM EST -
Discussing the potential of Zuranolone (SAGE-217) in Major Depressive Disorder before NDA expected in the 2nd Half of 2022
Ticker: SAGE
Executed On: Jan 27, 2022 at 02:00 PM EST
Upcoming & Overdue Catalysts (SAGE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (SAGE)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
